Gout is overall a neglected disease. Most audits and studies evaluating the management of the disease show, even in the most developed countries, that diagnosis is not necessarily based on standards, the burden of disease is not considered, and pain killers, and not urate-lowering therapy, still account for the most common prescriptions.

In this special issue EMD welcomes submissions regarding the evaluation such as evaluation of burden of disease, accommodation of prescriptions to recommendations and guidelines, evaluation of outcomes either laboratory (target serum urate levels), clinical (flares, patient reported outcomes/PROs), and imaging.

Last, but not least, pharmacoeconomic studies and patient’s reported expectations/PREs would also be included.

Keywords: Gout, management, evaluation, audits, burden of disease